{"id":7457,"date":"2025-06-25T17:15:09","date_gmt":"2025-06-25T14:15:09","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7457"},"modified":"2025-06-25T17:15:09","modified_gmt":"2025-06-25T14:15:09","slug":"summary-new-drug-combinations-could-cut-heart-failure-mortality-by-60","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-new-drug-combinations-could-cut-heart-failure-mortality-by-60\/","title":{"rendered":"Summary: New Drug Combinations Could Cut Heart Failure Mortality by 60%"},"content":{"rendered":"
Summary: New Drug Combinations Could Cut Heart Failure Mortality by 60%<\/div>\n
1. Early Initiation of Therapy:<\/div>\n
– HF treatment should begin immediately after diagnosis, alongside identifying underlying causes.<\/div>\n
– Benefits appear quickly with early intervention.<\/div>\n
<\/div>\n
2. Recommended Quadruple Therapy (ESC 2021):<\/div>\n
– For HFrEF (LVEF \u2264 40%) and mildly reduced EF (LVEF 41\u201349%):<\/div>\n
\u00a0\u2022 ACE inhibitors or ARNI<\/div>\n
\u00a0\u2022 Beta-blockers<\/div>\n
\u00a0\u2022 Mineralocorticoid receptor antagonists (MRAs)<\/div>\n
\u00a0\u2022 SGLT2 inhibitors<\/div>\n
– Loop diuretics added for volume overload.<\/div>\n
<\/div>\n
3. Supporting Evidence:<\/div>\n
– PARADIGM-HF and dapagliflozin trials showed mortality and hospitalization reduction within 30 and 27 days, respectively.<\/div>\n
<\/div>\n
4. Delayed Diagnosis is a Barrier: <\/span>Only 29% of patients with NT-proBNP > 2000 ng\/L were diagnosed with HF within 1 year (REVOLUTION HF study).<\/div>\n
\u2022 Average time to first echocardiography: 40 days.<\/span><\/div>\n
\u2022 BNP and NT-proBNP are crucial biomarkers in diagnosing HF. Elevated levels indicate increased cardiac wall stress\u2014a hallmark of HF.<\/span><\/div>\n
\u2022 BNP >100 pg\/mL \u2192 Sensitivity: 90%, Specificity: 76%<\/span><\/div>\n
\u2022 NT-proBNP >900 pg\/mL \u2192 Sensitivity: 90%, Specificity: 85%<\/span><\/div>\n
\u2022 NT-proBNP <300 pg\/mL effectively excludes acute HF with Sensitivity: 99%, Specificity: 68%<\/span><\/div>\n
– Interpretation must consider age, renal function, and BMI.<\/div>\n
5. Diagnostic Gaps Increase Mortality:<\/div>\n
– Lower natriuretic peptide levels often lead to missed diagnoses and untreated patients\u2014resulting in higher mortality.<\/div>\n
<\/div>\n
6. Treatment Sequence Recommendation:<\/div>\n
– Week 1: Start SGLT2 inhibitors, assess tolerability.<\/div>\n
– Week 2: Add MRAs.<\/div>\n
– Weeks 3\u20136: Gradually titrate beta-blockers.<\/div>\n
– Weeks 6\u201310: Start and titrate ARNI once BP is stable.<\/div>\n
– Flexibility: SGLT2i + MRAs may start together; beta-blockers may be introduced earlier if tolerated.<\/div>\n
<\/div>\n
7. Survival Benefits:<\/div>\n
– Switching from dual to quadruple therapy adds:<\/div>\n
\u00a0\u2022 +6.3 years of life for a 55-year-old.<\/div>\n
\u00a0\u2022 +1.4 years for an 80-year-old.<\/div>\n
– These gains reflect an estimated 60% reduction in heart failure mortality, based on cumulative evidence from key clinical trials.<\/div>\n
– Each of the four foundational drug classes has shown the following independent mortality and morbidity reductions:<\/div>\n
\u00a0\u2022 ARNI (e.g., sacubitril\/valsartan \u2013 PARADIGM-HF): \u2193 CV death or HF hospitalization by ~20%<\/div>\n
\u00a0\u2022 Beta-blockers (e.g., bisoprolol, metoprolol \u2013 MERIT-HF, CIBIS-II): \u2193 all-cause mortality by ~34%<\/div>\n
\u00a0\u2022 MRAs (e.g., spironolactone \u2013 RALES, eplerenone \u2013 EMPHASIS-HF): \u2193 CV mortality by ~30%<\/div>\n
\u00a0\u2022 SGLT2 inhibitors (e.g., dapagliflozin \u2013 DAPA-HF, empagliflozin \u2013 EMPEROR-Reduced): \u2193 CV death or HF hospitalization by ~25%<\/div>\n
– When used together, these therapies result in a cumulative benefit due to partially overlapping mechanisms and shared outcomes, leading to a powerful overall impact\u2014without simply summing individual effects.<\/div>\n
<\/div>\n
8. Implementation Challenges:<\/div>\n
– Quadruple therapy is still underutilized.<\/div>\n
– Telemonitoring is not widely adopted, despite its benefits.<\/div>\n
<\/div>\n
9. Device Therapy for Worsening HF:<\/div>\n
– Includes pacemakers, ICDs, CRT devices, and remote monitoring.<\/div>\n
– Essential for patients unresponsive to drugs.<\/div>\n
<\/div>\n
10. Arrhythmia Control:<\/div>\n
– Rhythm control in HF with atrial fibrillation can reduce both mortality and hospitalization.<\/div>\n
<\/div>\n
11. Emerging Drug \u2013 Vericiguat:<\/div>\n
– A soluble guanylate cyclase stimulator for worsening HF or drug intolerance.<\/div>\n
– Effective even at eGFR as low as 15 mL\/min.<\/div>\n
– VICTOR trial results expected in 2024.<\/div>\n
<\/div>\n
12. Iron Deficiency Management:<\/div>\n
– IV ferric carboxymaltose (Class IIa): improves symptoms and reduces rehospitalization.<\/div>\n
– Meta-analysis: 28% reduction in HF hospitalization + CV death.<\/div>\n
<\/div>\n
13. HFpEF Management:<\/div>\n
– Current: SGLT2 inhibitors, diuretics, comorbidity control.<\/div>\n
– Future: Finerenone (non-steroidal MRA) from FINEARTS-HF trial.<\/div>\n
\u00a0\u2022 Reduced HF events and CV death.<\/div>\n
\u00a0\u2022 May be included in 2026 ESC guidelines.<\/div>\n
https:\/\/click.mail.medscape.com\/?qs=b2cab64f70685f3b97f45d0508d2eee29b0eafd91ab05fc517d6e8535c337988af7c3c565c0d9cc814e8eecf97a6e83ea78b01fdf4ac70993ecbd0faa39a9ca3<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Summary: New Drug Combinations Could Cut Heart Failure Mortality by 60% 1. Early Initiation of Therapy: – HF treatment should begin immediately after diagnosis, alongside identifying underlying causes. – Benefits appear quickly with early intervention. 2. Recommended Quadruple Therapy (ESC 2021): – For HFrEF (LVEF \u2264 40%) and mildly reduced EF (LVEF 41\u201349%): \u00a0\u2022 ACE […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7457","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7457"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7457\/revisions"}],"predecessor-version":[{"id":7469,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7457\/revisions\/7469"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}